TG Therapeutics (NASDAQ:TGTX) versus Gilead Sciences (NASDAQ:GILD) Head to Head Comparison

TG Therapeutics (NASDAQ:TGTX) and Gilead Sciences (NASDAQ:GILD) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for TG Therapeutics and Gilead Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1	1	6	1	2.78
Gilead Sciences	0	6	23	0	2.79

TG Therapeutics currently has a consensus price target of $63.00, suggesting a potential downside of 4.20%. Gilead Sciences has a consensus price target of $170.15, suggesting a potential upside of 0.25%. Given Gilead Sciences’ stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than TG Therapeutics.

Institutional & Insider Ownership

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

TG Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Profitability

This table compares TG Therapeutics and Gilead Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	11.81%	18.82%	7.78%
Gilead Sciences	-12.47%	-1.85%	-0.61%

Earnings and Valuation

This table compares TG Therapeutics and Gilead Sciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29 million	16.13	$447.18 million	$0.66	99.64
Gilead Sciences	$29.44 billion	7.15	$8.51 billion	($3.16)	-53.71

Gilead Sciences has higher revenue and earnings than TG Therapeutics. Gilead Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

TG Therapeutics beats Gilead Sciences on 8 of the 14 factors compared between the two stocks.

About TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.